title: One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome.
abstract: BACKGROUND
  This study sought to investigate the effects of omega (ω)-3 polyunsaturated fatty acid (PUFA) supplementation on the lipid profiles and glucose (GLU) levels of overweight (OW) schoolchildren with metabolic syndrome (MS).
  
  
  METHODS
  Thirty-nine OW schoolchildren with MS, including 19 girls and 20 boys, received 1-month of dietary supplementation with gel capsules containing ω-3 fatty acids. Fasting lipid profiles and GLU levels were measured before and after supplementation.
  
  
  RESULTS
  Both sexes of OW schoolchildren with MS who received daily supplementation with 2.4 g of ω-3 fatty acids for 1 month displayed improved lipid profiles, reduced fasting GLU levels and reduced blood pressure (BP).
  
  
  CONCLUSIONS
  These findings support the addition of omega-3 fatty acid supplementation to programs aiming to improve the metabolic status of OW children with MS, although additional research on the longer-term safety and efficacy of this treatment in this population is required.
authors.forename: Salvador
authors.initials: S
authors.lastname: García-López
authors.forename: Rosina E
authors.initials: RE
authors.lastname: Villanueva Arriaga
authors.forename: Oralia
authors.initials: O
authors.lastname: Nájera Medina
authors.forename: Carmen Paulina
authors.initials: CP
authors.lastname: Rodríguez López
authors.forename: Lauro
authors.initials: L
authors.lastname: Figueroa-Valverde
authors.forename: Elodia García
authors.initials: EG
authors.lastname: Cervera
authors.forename: Octavio
authors.initials: O
authors.lastname: Muñozcano Skidmore
authors.forename: Marcela
authors.initials: M
authors.lastname: Rosas-Nexticapa
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D050177:Overweight / Q000150:complications*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D015525:Fatty Acids, Omega-3; D008055:Lipids